MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1 Retraction in /10.3892/ijmm.2021.5013

Wang,Shu; Sun,Hongmei; Zhan,Xiaokai; Wang,Qiwen

doi:10.3892/ijmm.2019.4396

MicroRNA‑718 serves a tumor‑suppressive role in non‑small cell lung cancer by directly targeting CCNB1

Retraction in: /10.3892/ijmm.2021.5013

Authors:
- Shu Wang
- Hongmei Sun
- Xiaokai Zhan
- Qiwen Wang
View Affiliations

Affiliations: Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Thoracic Oncosurgery, Jilin Province Tumor Hospital, Changchun, Jilin 130012, P.R. China
Published online on: November 4, 2019 https://doi.org/10.3892/ijmm.2019.4396
Pages: 33-44
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑718 (miR‑718) serves crucial roles in tumorigenesis and in the progression of a number of cancers. However, the expression profile, specific functions and mechanisms of action of miR‑718 in non‑small cell lung cancer (NSCLC) are still elusive. The aims of the present study were to quantify the expression of miR‑718, determine its biological roles and elucidate the molecular mechanisms responsible for its activities in NSCLC cells. Reverse transcription‑quantitative PCR was carried out to assess miR‑718 expression in NSCLC tissue samples and cell lines. The Cell Counting Kit‑8 assay, flow cytometry, cell migration and invasion assays, and a tumor xenograft experiment were performed to evaluate the effects of miR‑718 overexpression on the malignant biological behaviors of NSCLC cells. miR‑718 expression was demonstrated to be significantly decreased in NSCLC tissue samples and cell lines. This reduced expression was significantly associated with tumor, node, metastasis stage, tumor size, lymph node metastasis and poor overall survival among patients with NSCLC. Exogenous miR‑718 expression suppressed NSCLC cell proliferation, migration and invasion, and promoted apoptosis in vitro; whereas it hindered tumor growth in vivo. Experiments to elucidate the mechanisms involved revealed that miR‑718 functions by directly targeting cyclin B1 (CCNB1) mRNA. CCNB1 expression was found to be upregulated in NSCLC and inversely correlated with miR‑718 levels. CCNB1 depletion had effects similar to those of miR‑718 overexpression in NSCLC cells. Furthermore, restoration of CCNB1 expression attenuated the tumor‑suppressive effects of miR‑718 overexpression in NSCLC cells. These results indicated that miR‑718 suppressed NSCLC progression in vitro and in vivo by directly targeting CCNB1 mRNA, which may indicate a potential target for the diagnosis and treatment of this fatal disease.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Duma N, Santana-Davila R and Molina JR: Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ma L, Qiu B, Zhang J, Li QW, Wang B, Zhang XH, Qiang MY, Chen ZL, Guo SP and Liu H: Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy. Chin J Cancer. 36:932017. View Article : Google Scholar : PubMed/NCBI
6	Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhag D and Zhu S: Targeted therapies for advanced non-small cell lung cancer. Oncotarget. 9:37589–37607. 2018. View Article : Google Scholar
7	Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ. 24:1205–1213. 2017. View Article : Google Scholar :
8	Mao M, Wu Z and Chen J: MicroRNA-187-5p suppresses cancer cell progression in non-small cell lung cancer (NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
9	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10	Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
11	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
12	Rao C, Miao X, Zhao G, Zhang C, Shen H, Dong C and Yang M: MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9. Biomed Pharmacother. 114:1086622019. View Article : Google Scholar : PubMed/NCBI
13	Wu W, He L, Huang Y, Hou L, Zhang W, Zhang L and Wu C: MicroRNA-510 plays oncogenic roles in non-small cell lung cancer by directly targeting SRC kinase signaling inhibitor 1. Oncol Res. 27:879–887. 2019. View Article : Google Scholar : PubMed/NCBI
14	Zhang MY, Lin J and Kui YC: MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1. Eur Rev Med Pharmacol Sci. 23:2436–2443. 2019.PubMed/NCBI
15	Liu S, Tian Y, Zhu C, Yang X and Sun Q: High miR-718 suppresses phosphatase and tensin homolog (PTEN) expression and correlates to unfavorable prognosis in gastric cancer. Med Sci Monit. 24:5840–5850. 2018. View Article : Google Scholar : PubMed/NCBI
16	Leng R, Zha L and Tang L: MiR-718 represses VEGF and inhibits ovarian cancer cell progression. FEBS Lett. 588:2078–2086. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wang X and Qi M: miR-718 is involved in malignancy of papillary thyroid cancer through repression of PDPK1. Pathol Res Pract. 214:1787–1793. 2018. View Article : Google Scholar : PubMed/NCBI
18	Wang ZD, Qu FY, Chen YY, Ran ZS, Liu HY and Zhang HD: Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells. J Zhejiang Univ Sci B. 18:27–36. 2017. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
20	Cooper WA, Kohonen-Corish MR, McCaughan B, Kennedy C, Sutherland RL and Lee CS: Expression and prognostic signifi-cance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 55:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yoshida T, Tanaka S, Mogi A, Shitara Y and Kuwano H: The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 15:252–256. 2004. View Article : Google Scholar : PubMed/NCBI
22	Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Kimura Y and Uchida Y: Clinical implication of cyclin B1 in non-small cell lung cancer. Oncol Rep. 10:1381–1386. 2003.PubMed/NCBI
23	Zhang LL, Feng ZL, Su MX, Jiang XM, Chen X, Wang Y, Li A, Lin LG and Lu JJ: Downregulation of Cyclin B1 mediates nagi-lactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells. Eur J Pharmacol. 830:17–25. 2018. View Article : Google Scholar : PubMed/NCBI
24	Kedinger V, Meulle A, Zounib O, Bonnet ME, Gossart JB, Benoit E, Messmer M, Shankaranarayanan P, Behr JP, Erbacher P, et al: Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases. BMC Cancer. 13:3382013. View Article : Google Scholar : PubMed/NCBI
25	Mateen S, Raina K, Jain AK, Agarwal C, Chan D and Agarwal R: Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 7:1161–1172. 2012. View Article : Google Scholar : PubMed/NCBI
26	Zuryn A, Gagat M, Grzanka AA, Gackowska L and Grzanka A: Expression of cyclin B1 after induction of senescence and cell death in non-small cell lung carcinoma A549 cells. Folia Histochem Cytobiol. 50:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhuang XF, Zhao LX, Guo SP, Wei S, Zhai JF and Zhou QH: miR-34b inhibits the migration/invasion and promotes apoptosis of non-small-cell lung cancer cells by YAF2. Eur Rev Med Pharmacol Sci. 23:2038–2046. 2019.PubMed/NCBI
28	Gao J, Feng X, Wang F, Wang J, Wang H, Li H, Zhang W, Hao L and Shi Z: microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2. J Cell Biochem. 120:13453–13463. 2019. View Article : Google Scholar : PubMed/NCBI
29	Li H, Jiang M, Cui M, Feng G, Dong J, Li Y, Xiao H and Fan S: MiR-365 enhances the radiosensitivity of non-small cell lung cancer cells through targeting CDC25A. Biochem Biophys Res Commun. 512:392–398. 2019. View Article : Google Scholar : PubMed/NCBI
30	Weidle UH, Birzele F and Nopora A: MicroRNAs as potential targets for therapeutic intervention with metastasis of non-small cell lung cancer. Cancer Genomics Proteomics. 16:99–119. 2019. View Article : Google Scholar : PubMed/NCBI
31	Wang H, Ma Z, Liu X, Zhang C, Hu Y, Ding L, Qi P, Wang J, Lu S and Li Y: MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN. Biomed Pharmacother. 111:1103–1111. 2019. View Article : Google Scholar : PubMed/NCBI
32	Ma Y, Li X, Chen S, Du B and Li Y: MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells. Cancer Manag Res. 11:637–649. 2019. View Article : Google Scholar : PubMed/NCBI